Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospit...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

Kocatka Jul. 4 at 5:29 PM

$LXRX Big Decision While I don't have any material information on current discussions within company. At this moment, I have to believe there is genuine interest from Novo making a serious buyout offer for as opposed to another partnership with the Steno Trial Data in house. Lexicon is not hiring a salesforce for the T1D indication and that will need to be in place by the 4th Qtr. They have put the LX9211 PILA discussion on the backburner, this is another indication of priority. Timing for this seems right.

2 · Reply

Dooright Jul. 4 at 3:56 PM

$LXRX Happy 4th everyone! If you look at the 6 month chart it really is a thing of beauty! Higher highs and higher lows, each cycle bouncing right off the 50 DMA., which on the 6 month currently sits at $2.02. RSI now back around 60, which is not super overbought. We may continue in a bit of a pullback for now, but I think the next bounce near or off the 50 DMA will take us to a new 52 week high above $3.00. Exton will release news when he can. For now, no news is good news. I just hope the next release is not about another presentation at a clinical conference or fireside chat. If that happens, I might just kill myself! (Kidding). My best guess is that our next 52 week high will happen around the end of July or early August. Hopefully sooner, but I can wait patiently! Godspeed to all. Doc C. 🤓

1 · Reply

wildwesttrader Jul. 3 at 7:50 PM

$LXRX no pullback. Just daily fluctuations and a steady climb once news hits. It will hit and the shorts will pay. Have a great 4th!!

0 · Reply

LionNoRichy Jul. 3 at 7:22 PM

$LXRX so many negative ppl that reading this board is tiring xd

0 · Reply

atreus57 Jul. 3 at 7:05 PM

$LXRX definitely will grow very quickly at 3 and then all the way towards $7... Will buy some more on monday if I don't miss it... it's going to grow fast...

0 · Reply

MYFLAUT Jul. 3 at 6:51 PM

$LXRX working overtime stacking up some cash getting ready for a well it’s only my opinion but I think we’re gonna have a severe pull back in just a few days. I’m ready to load the truck. Got two of the empty handtruck ready and straps tiedowns we’re gonna load the truck this time maybe need new springs

0 · Reply

atreus57 Jul. 3 at 4:02 PM

$LXRX my waiting time on a stock is 2-5 years, I am not only not in a rush, from my perspective, this is quite an early growth...

0 · Reply

alcat1973 Jul. 3 at 12:25 PM

$LXRX You all understand that any bad news will drive this back down to 1.50. This is where the mm's (market manipulators) really hold you hostage. You either put your trust in Lexi management or bail taking much less than desired profit. I never feel good watching a stock drop like this in anticipation of "good" news coming. No buyer, no FDA update and looking like another down day.

1 · Reply

alcat1973 Jul. 2 at 9:47 PM

$LXRX 5 day chart tells the story. Up 40 cents...then down 40 cents. Not unusual for this psycho stock. Tick tock...July and still crickets. Partnership? FDA update? I thought earnings update we would here something by now. Share price still in a good place but one of these days I would like to move on. Not a big fan of roller coasters.

1 · Reply

gucag006 Jul. 2 at 9:35 PM

$LXRX Still guessing, nothing definitive, but Gemini's guessing is better than mine:

2 · Reply

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:00 AM EDT - 4 weeks ago

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

May 28, 2026, 8:30 AM EDT - 5 weeks ago

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 26, 2026, 7:00 AM EDT - 5 weeks ago

Lexicon Pharmaceuticals Slides: Investor presentation

May 19, 2026, 4:30 PM EDT - 6 weeks ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

2026-05-11T11:01:50.000Z - 7 weeks ago

Lexicon price target raised to $3.10 from $2.30 at Citi

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

May 4, 2026, 4:05 PM EDT - 2 months ago

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

HTGC

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-17T12:22:28.000Z - 2 months ago

Lexicon to present data at AAN annual meeting on Progress Phase 2b study

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

2026-03-23T11:46:37.000Z - 3 months ago

Lexicon, Novo Nordisk announce initiation of LX9851 study

NVO

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 11, 2026, 10:00 AM EDT - 4 months ago

Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-11T12:17:17.000Z - 4 months ago

Lexicon announces results from post hoc analysis on data of sotagliflozin

Mar 11, 2026, 8:00 AM EDT - 4 months ago

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

2026-03-10T10:53:36.000Z - 4 months ago

Lexicon price target raised to $2.30 from $2.10 at Citi

2026-03-05T16:06:30.000Z - 4 months ago

Lexicon price target raised to $6 from $4 at H.C. Wainwright

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Slides: Q4 2025

2026-03-05T12:08:49.000Z - 4 months ago

Lexicon reports Q4 EPS (4c), consensus (7c)

Mar 5, 2026, 6:59 AM EST - 4 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 4:01 PM EST - 4 months ago

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Feb 26, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Feb 17, 2026, 7:00 AM EST - 4 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Feb 6, 2026, 5:17 PM EST - 5 months ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 30, 2026, 2:50 AM EST - 5 months ago

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

2026-01-29T21:36:16.000Z - 5 months ago

Lexicon announces common stock offering, no amount given

Jan 29, 2026, 4:31 PM EST - 5 months ago

Lexicon Announces Proposed Public Offering of Common Stock

Jan 23, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

2026-01-21T13:42:01.000Z - 5 months ago

Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin

Jan 21, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Jan 20, 2026, 6:59 AM EST - 5 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

VTRS

Jan 15, 2026, 3:00 PM EST - 6 months ago

Lexicon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 3:00 PM EST - 6 months ago

Lexicon Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-14T10:45:10.000Z - 6 months ago

Lexicon price target raised to $2.10 from $1.90 at Citi

2026-01-12T12:55:44.000Z - 6 months ago

Lexicon sees cash runway into 2027

Jan 12, 2026, 7:30 AM EST - 6 months ago

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-09T13:40:14.000Z - 6 months ago

Lexicon publishes White Paper on treatments for chronic pain

Jan 9, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Jan 7, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-10T13:40:17.000Z - 7 months ago

Lexicon announces publication of preclinical data on ACSL5

NVO

Dec 10, 2025, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 5, 2025, 8:30 AM EST - 7 months ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Dec 4, 2025, 9:10 AM EST - 7 months ago

Lexicon Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 9:00 AM EST - 7 months ago

Lexicon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 18, 2025, 12:00 PM EST - 8 months ago

Lexicon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Lexicon Pharmaceuticals Slides: Corporate presentation

Nov 11, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

2025-11-09T18:20:08.000Z - 8 months ago

Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025

Nov 8, 2025, 2:30 PM EST - 8 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Slides: Q3 2025

2025-11-06T12:41:13.000Z - 8 months ago

Lexicon reports Q3 EPS (4c), consensus (7c)

Nov 6, 2025, 7:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 4, 2025, 8:30 AM EST - 8 months ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 9 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 10 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 2:30 PM EDT - 10 months ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 1:45 PM EDT - 10 months ago

Lexicon Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 10 months ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Slides: Q2 2025

Aug 6, 2025, 7:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Corporate Presentation

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 20, 2025, 9:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Kocatka Jul. 4 at 5:29 PM

2 · Reply

Dooright Jul. 4 at 3:56 PM

1 · Reply

wildwesttrader Jul. 3 at 7:50 PM

$LXRX no pullback. Just daily fluctuations and a steady climb once news hits. It will hit and the shorts will pay. Have a great 4th!!

0 · Reply

LionNoRichy Jul. 3 at 7:22 PM

$LXRX so many negative ppl that reading this board is tiring xd

0 · Reply

atreus57 Jul. 3 at 7:05 PM

$LXRX definitely will grow very quickly at 3 and then all the way towards $7... Will buy some more on monday if I don't miss it... it's going to grow fast...

0 · Reply

MYFLAUT Jul. 3 at 6:51 PM

0 · Reply

atreus57 Jul. 3 at 4:02 PM

$LXRX my waiting time on a stock is 2-5 years, I am not only not in a rush, from my perspective, this is quite an early growth...

0 · Reply

alcat1973 Jul. 3 at 12:25 PM

1 · Reply

alcat1973 Jul. 2 at 9:47 PM

1 · Reply

gucag006 Jul. 2 at 9:35 PM

$LXRX Still guessing, nothing definitive, but Gemini's guessing is better than mine:

2 · Reply

guimark Jul. 2 at 9:04 PM

$LXRX 🖕

0 · Reply

liloleme4 Jul. 2 at 7:43 PM

$LXRX Hopefully you sold - it gives the rest of us better odds for it going up ;)

0 · Reply

rachelkiss Jul. 2 at 6:45 PM

$LXRX Normal profit taking and frightened newbies. It'll go back up

0 · Reply

Dooright Jul. 2 at 6:39 PM

$LXRX Yes, please sell. Schmuck! 😆 Doc C. 🤓

0 · Reply

SniperPro Jul. 2 at 5:41 PM

$INTC $NVDA $LXRX $TSLA $ORCL WTF IS RED DAY? 💥🚀 250th anniversary... we're "winning" so much. What kind of joke is this? 🤡 70% of my portfolio is red. FFS, I'm a patriot, but red isn't the only color on the flag. 🤣 ..

0 · Reply

guimark Jul. 2 at 5:40 PM

$LXRX think I will just sell it all off after holding for so many years . I honestly think that Lexicon will probably never get a decent break and we will be looking at people on here saying $7 -$10 soon …for years😊 Cheap convertible soon for me …. I’m no a pro and its the only bit of stock I own at the minute and in a bit of profit now .

0 · Reply

Hatrak1 Jul. 2 at 4:24 PM

$LXRX Working out to be the perfect cup and handle ! 😁 You know my problem was not with the fact that it dropping, but with the way you framed it ! When I was new it was really tough watching guys like you take advantage of those less experienced when this platform should be used to help them learn. I've just made it a point to call out the bullshit ! Your price target was pretty damned spot on, but your tactics suck ! 😁🤷‍♂️👍

1 · Reply

ChrisBAB Jul. 2 at 4:01 PM

$LXRX Enough with the cups, let's trace that handle! ☕ $NIXX Next week could be interesting... Compliance ✅ $NEOV 👀 Looking for entry below $2.45

0 · Reply

Buttermaker007 Jul. 2 at 3:51 PM

$LXRX for some people it’s their last week with all ten digits ! Stay blessed everybody

0 · Reply

SniperPro Jul. 2 at 2:44 PM

$LXRX HE'S TRYING TO SQUEEZE HIS TESTIS OUT... 🤣 TOO LATE.

0 · Reply

SniperPro Jul. 2 at 2:43 PM

$LXRX Michaela extonia also known as cryptorchidismic australianis... 🤣🤡 Some men are born with testicles... Others spend so much time searching for theirs that conviction never makes an appearance... Courage, it turns out, isn't an anatomical feature—it's a character trait, and no amount of posturing can substitute for it... MIKE POS, WTF ARE YOU WAITING FOR? RAY d, SHAME ON YOU! 🤡 TICK TOCK DUMBFVCKS!!! 👹 ...

0 · Reply

beezee8 Jul. 2 at 2:38 PM

$LXRX Quick reminder before anyone lays into Bobby - he has popped up at the best buying opportunities.

0 · Reply

Market Cap	1.03B
Revenue (ttm)	49.80M
Net Income (ttm)	-50.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-101.08%
Debt to Equity Ratio	0.24

Volume	2,630,000
Avg Vol	3,443,890
Day's Range	N/A - N/A
Shares Out	444.20M
Stochastic %K	48%
Beta	1.05
Analysts	Sell
Price Target	$3.77